Encoded Raises $275 Million for ETX101 Pivotal Development
Encoded Therapeutics closed a $275 million Series F financing to fund pivotal development of ETX101 in SCN1A-positive Dravet syndrome, expand development through age 18, scale its internal GMP manufacturing operation and advance ETX301 toward…
